AMYT Amryt Pharma

Holding(s) in Company

Holding(s) in Company

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Amryt Pharma PLC

GB00BKLTQ412
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rights 
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
NameUBS Asset Management - O'Connor

UBS Group AG
City and country of registered office (if applicable)Zürich, Switzerland
4. Full name of shareholder(s) (if different from 3.)v
NameUBS O'Connor LLC
City and country of registered office (if applicable)Wilmington, USA
5. Date on which the threshold was crossed or reachedvi:22 September 2020
6. Date on which issuer notified (DD/MM/YYYY):29 September 2020
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached2.60%3.53%6.13%162'728'640
Position of previous notification (if

applicable)
N/AN/AN/A 


8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of

shares


ISIN code (if possible)
Number of voting rightsix% of voting rights
Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BKLTQ412 4'229'753 2.60%
     
     
SUBTOTAL 8. A4'229'7532.60%
 



 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration

date
x
Exercise/

Conversion Period
xi
Number of voting rights that may be acquired if the instrument is

exercised/converted.
% of voting rights
US03217L1061  5'742'6203.53%
     
     
  SUBTOTAL 8. B 15'742'6203.53%
 



 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration

date
x
Exercise/

Conversion Period
xi
Physical or cash

settlementxii
Number of voting rights % of voting rights
      
      
      
   SUBTOTAL 8.B.2  
 



 



 



9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii 
Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
UBS Group AG   
UBS AG   
UBS Americas Holding LLC   
UBS O'Connor LLC- 3.53%6.13 %
    
    
    
    



 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 



 



 



 



 
11. Additional informationxvi
 



Place of completionOpfikon, Switzerland
Date of completion29.09.2020

EN
30/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amryt Pharma

 PRESS RELEASE

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming...

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide - Acromegaly patients were exposed to Mycapssa® during the global Open-Label Extension (OLE) of the MPOWERED Phase 3 Trial for a maximum o...

 PRESS RELEASE

Key Dates for AIM Delisting

Key Dates for AIM Delisting Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6, 2022, Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“Amryt” or the “Company”), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today reminds shareholders of the key dates concerning the cancellation of the admission of its ordinary shares of nominal value £0.06 each (the “Ordinary Shares”) to trading on AIM (the “AIM Delisting”), as originally announced on November 22, 2021. As pr...

 PRESS RELEASE

The Lancet Diabetes & Endocrinology Publishes Positive Results for the...

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that The Lancet Diabetes & Endocrinology has published ...

 PRESS RELEASE

Total Voting Rights

Total Voting Rights Total Voting Rights DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on December 31, 2021 the issued share capital of the Company comprised 319,814,747 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company at December 31, 2021 was 319,814,747.  This figure of...

 PRESS RELEASE

Total Voting Rights

Total Voting Rights Total Voting Rights DUBLIN, Ireland, and Boston MA, December 1, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on November 30, 2021 the issued share capital of the Company comprised 319,657,247 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company at November 30, 2021 was 319,657,247.  This figure of 31...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch